A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

Cited by (1,004)

Items 401–500 of 1,004

1. Overview of Targets and Potential Drugs of SARS-CoV-2 According to the Viral Replication
   Yi Zhang, Liang V. Tang · 2020 · Journal of Proteome Research
2. Quantitative assays reveal cell fusion at minimal levels of SARS-CoV-2 spike protein and fusion from without
   Samuel A. Theuerkauf, Alexander Michels, Vanessa Riechert, Thorsten J. Maier, Egbert Flory, Klaus Cichutek, Christian J. Buchholz · 2021 · iScience
3. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2
   Javed Akhter, Grégory Quéromès, Krishna Pillai, Vahan Képénékian, Samina Badar, Ahmed H. Mekkawy, Émilie Frobert, Sarah J. Valle, David Lawson Morris · 2021 · Viruses
4. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro
   Jeremy Ra Paull, Graham P. Heery, Michael D. Bobardt, Alex Castellarnau, Carolyn A. Luscombe, Jacinth K. Fairley, Philippe A. Gallay · 2021 · Antiviral Research
5. SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review
   Jahangir Emrani, Maryam Ahmed, Liesl K. Jeffers-Francis, John C. Teleha, Chishimba Nathan Mowa, Robert Howard Newman, Misty D. Thomas · 2021 · International Journal of Biological Macromolecules
6. Intranasal delivery of SARS-CoV-2 spike protein is sufficient to cause olfactory damage, inflammation and olfactory dysfunction in zebrafish
   Aurora Kraus, Mar Huertas, Laura V. Ellis, Pierre Boudinot, Jean‐Pierre Levraud, Irene Salinas · 2022 · Brain Behavior and Immunity
7. Protective neutralizing epitopes in SARS‐CoV‐2
   Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
8. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
   Raquel Pérez-Gómez · 2021 · Journal of Developmental Biology
9. SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron
   Matthew T. Laurie, Jamin Liu, Sara Sunshine, James Peng, Douglas Black, Anthea M. Mitchell, Sabrina A Mann, Genay O.W. Pilarowski, Kelsey C. Zorn, Luis Rubio et al. · 2022 · The Journal of Infectious Diseases
10. Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences
    Reem Hoteit, Hadi Mohamad Yassine · 2022 · Vaccines
11. Altered host protease determinants for SARS-CoV-2 Omicron
    Jasper Fuk‐Woo Chan, Xiner Huang, Bingjie Hu, Yue Chai, Hongyu Shi, Tianrenzheng Zhu, Terrence Tsz‐Tai Yuen, Yuanchen Liu, Huan Liu, Jialu Shi et al. · 2023 · Science Advances
12. C1 esterase inhibitor and the contact system in COVID‐19
    Timothy M. Thomson, Emily Toscano, Ernesto Casís, Rosanna Paciucci · 2020 · British Journal of Haematology
13. Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
    Enya Qing, Pengfei Li, Laura M. Cooper, Sebastian R. Schulz, Hans‐Martin Jäck, Lijun Rong, Stanley M. Perlman, Tom Gallagher · 2022 · Cell Reports
14. Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2
    Mariana F. Tioni, Robert Jordan, Angie Silva Pena, Aditya Garg, Danlu Wu, Shannon I. Phan, Christopher M. Weiss, Xing Cheng, Jack J. Greenhouse, Tatyana Orekov et al. · 2022 · npj Vaccines
15. Identification and differential usage of a host metalloproteinase entry pathway by SARS-CoV-2 Delta and Omicron
    Mehdi Benlarbi, Geneviève Laroche, Corby Fink, Kathy Fu, Rory P. Mulloy, Alexandra Phan, Ardeshir Ariana, Corina M. Stewart, Jérémie Prévost, Guillaume Beaudoin-Bussières et al. · 2022 · iScience
16. Variations in SARS-CoV-2 Spike Protein Cell Epitopes and Glycosylation Profiles During Global Transmission Course of COVID-19
    Wenxin Xu, Mingjie Wang, Demin Yu, Xinxin Zhang · 2020 · Frontiers in Immunology
17. Expression of SARS-CoV-2 entry factors in lung epithelial stem cells and its potential implications for COVID-19
    Anna A. Valyaeva, Anastasia A. Zharikova, Artem S. Kasianov, Yegor S Vassetzky, Eugene V. Sheval · 2020 · Scientific Reports
18. SARS-CoV-2 Bearing a Mutation at the S1/S2 Cleavage Site Exhibits Attenuated Virulence and Confers Protective Immunity
    Michihito Sasaki, Shinsuke Toba, Yukari Itakura, Herman M. Chambaro, Mai Kishimoto, Koshiro Tabata, Kittiya Intaruck, Kentaro Uemura, Takao Sanaki, Akihiko Sato et al. · 2021 · mBio
19. Fibroblast-expressed LRRC15 is a receptor for SARS-CoV-2 spike and controls antiviral and antifibrotic transcriptional programs
    Lipin Loo, Matthew A. Waller, Cesar L. Moreno, Alexander J. Cole, Alberto Ospina Stella, Oltin-Tiberiu Pop, Ann-Kristin Jochum, Omar Hasan Ali, Christopher E. Denes, Zina Hamoudi et al. · 2023 · PLoS Biology
20. Flexible, Functional, and Familiar: Characteristics of SARS-CoV-2 Spike Protein Evolution
    Dianita S. Saputri, Songling Li, Floris J. van Eerden, John Rozewicki, Zichang Xu, Hendra Saputra Ismanto, Ana Davila, Shunsuke Teraguchi, Kazutaka Katoh, Daron M. Standley · 2020 · Frontiers in Microbiology
21. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat
    Gaohui Sun, Yaqun Sui, Yang Zhou, Junlin Ya, Cai Yuan, Longguang Jiang, Mingdong Huang · 2021 · Journal of Virology
22. Studying SARS-CoV-2 infectivity and therapeutic responses with complex organoids
    Kevin G. Chen, Kyeyoon Park, Jason R. Spence · 2021 · Nature Cell Biology
23. Spike residue 403 affects binding of coronavirus spikes to human ACE2
    Fabian Zech, Daniel Schniertshauer, Christoph Jung, Alexandra Herrmann, Arne Cordsmeier, Qinya Xie, Rayhane Nchioua, Caterina Prelli Bozzo, Meta Volčič, Lennart Koepke et al. · 2021 · Nature Communications
24. Identification of SARS-CoV-2 Spike Palmitoylation Inhibitors That Results in Release of Attenuated Virus with Reduced Infectivity
    Ahmed Ramadan, Karthick Mayilsamy, Andrew R. McGill, Anandita Ghosh, Marc A. Giulianotti, Haley M. Donow, Shyam S. Mohapatra, Subhra Mohapatra, Bala Chandran, Robert J. Deschenes et al. · 2022 · Viruses
25. A simple reverse genetics method to generate recombinant coronaviruses
    Julien Mélade, Géraldine Piorkowski, Franck Touret, Toscane Fourié, Jean‐Sélim Driouich, Maxime Cochin, Hawa Sophia Bouzidi, Bruno Coutard, Antoine Nougaırède, Xavier Nicolas de Lamballerie · 2022 · EMBO Reports
26. Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
    Jasper Fuk‐Woo Chan, Bingjie Hu, Yue Chai, Huiping Shuai, Huan Liu, Jialu Shi, Yuanchen Liu, Chaemin Yoon, Jinjin Zhang, Jingchu Hu et al. · 2022 · Cell Reports Medicine
27. Host barriers to SARS-CoV-2 demonstrated by ferrets in a high-exposure domestic setting
    Kaitlin Sawatzki, Nichola J. Hill, Wendy Blay Puryear, Alexa D. Foss, Jonathon J. Stone, Jonathan A. Runstadler · 2021 · Proceedings of the National Academy of Sciences
28. S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review
    Reza Nejat, Maziar Fayaz Torshizi, David J. Najafi · 2023 · Vaccines
29. Pulmonary fibrosis: A short- or long-term sequelae of severe COVID-19?
    Zhen Zheng, Fei Peng, Yong Zhou · 2023 · Chinese Medical Journal - Pulmonary and Critical Care Medicine
30. Coronaviruses: Is Sialic Acid a Gate to the Eye of Cytokine Storm? From the Entry to the Effects
    Przemysław Wielgat, Karol Rogowski, Katarzyna Godlewska, Halina Car · 2020 · Cells
31. COVID-19: a metaphor-based neologism and its translation into Arabic
    Amal Haddad Haddad, Silvia Montero Martínez · 2020 · Journal of Science Communication
32. Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms
    Jordan R. Yaron, Liqiang Zhang, Qiuyun Guo, Shelley E. Haydel, Alexandra Lucas · 2021 · Frontiers in Cardiovascular Medicine
33. Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells
    Seshu Vardhan, Suban Kumar Sahoo · 2021 · Journal of Traditional and Complementary Medicine
34. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain
    Zachariah P. Schuurs, Edward Hammond, Stefano Elli, Timothy Robert Rudd, Courtney J. Mycroft‐West, Marcelo Andrade de Lima, Mark Andrew Skidmore, Richard Torbjörn Gustav Karlsson, Yen‐Hsi Chen, Ieva Bagdonaite et al. · 2021 · Computational and Structural Biotechnology Journal
35. Mutations in the B.1.1.7 SARS-CoV-2 Spike Protein Reduce Receptor-Binding Affinity and Induce a Flexible Link to the Fusion Peptide
    Eileen Socher, Marcus Conrad, Lukas Heger, Friedrich P. Paulsen, Heinrich Sticht, Friederike Zunke, Philipp Arnold · 2021 · Biomedicines
36. Snake venom phospholipase A2s exhibit strong virucidal activity against SARS-CoV-2 and inhibit the viral spike glycoprotein interaction with ACE2
    Andrei E. Siniavin, Maria A. Streltsova, Maria A. Nikiforova, Denis S. Kudryavtsev, Svetlana D. Grinkina, Vladimir А. Gushchin, Vera A. Mozhaeva, Vladislav G. Starkov, Alexey V. Osipov, Sarah C. R. Lummis et al. · 2021 · Cellular and Molecular Life Sciences
37. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants
    Dibya Ghimire, Yang Han, Maolin Lu · 2022 · Viruses
38. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
    Iart Luca Shytaj, Mohamed Fares, Lara Gallucci, Bojana Lucic, Mahmoud M. Tolba, Liv Zimmermann, Julia Maria Adler, Na Xing, Judith Bushe, Achim Dieter Gruber et al. · 2022 · mBio
39. A novel PLpro inhibitor improves outcomes in a pre-clinical model of long COVID
    Stefanie M. Bader, Dale J. Calleja, Shane M. Devine, Nathan W. Kuchel, Bernadine G.C. Lu, Xinyu Wu, Richard W. Birkinshaw, Reet Bhandari, Katie Loi, Rohan Volpe et al. · 2025 · Nature Communications
40. COVID-19, COPD, and AECOPD: Immunological, Epidemiological, and Clinical Aspects
    Francesca Polverino, Farrah Kheradmand · 2021 · Frontiers in Medicine
41. Covid‐19 Infection and Parkinsonism: Is There a Link?
    Rabia Bouali‐Benazzouz, Abdelhamid Benazzouz · 2021 · Movement Disorders
42. Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection
    Hi Eun Jung, Heung Kyu Lee · 2021 · Viruses
43. SARS-CoV-2 Omicron variant escapes neutralizing antibodies and T cell responses more efficiently than other variants in mild COVID-19 convalescents
    Pablo García-Valtanen, Christopher M. Hope, Makutiro Ghislain Masavuli, Arthur Eng Lip Yeow, Harikrishnan Balachandran, Zelalem Addis Mekonnen, Zahraa Al-Delfi, Arunasingam Abayasingam, David Agapiou, Alberto Ospina Stella et al. · 2022 · Cell Reports Medicine
44. Estimation of Secondary Household Attack Rates for Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco
    Peng, James, Liu, Jamin, Mann, Sabrina A, Mitchell, Anthea M, Laurie, Matthew T, Sunshine, Sara, Pilarowski, Genay, Ayscue, Patrick, Kistler, Amy, Vanaerschot, Manu et al. · 2022 · Clinical Infectious Diseases
45. Kinetics and isotype assessment of antibodies targeting the spike protein receptor‐binding domain of severe acute respiratory syndrome‐coronavirus‐2 in COVID‐19 patients as a function of age, biological sex and disease severity
    Nancy R. Graham, Annalis Whitaker, Camilla A. Strother, Ashley K. Miles, Dore Grier, Benjamin D. McElvany, Emily A. Bruce, Matthew E. Poynter, Kristen K. Pierce, Beth D. Kirkpatrick et al. · 2020 · Clinical & Translational Immunology
46. A comprehensive review on potential therapeutics interventions for COVID-19
    Heerak Chugh, Amardeep Awasthi, Yashi Agarwal, Rajesh K Gaur, Gagan Dhawan, Ramesh Chandra · 2020 · European Journal of Pharmacology
47. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-CoV-2 infection
    Jin Wei, Ajinkya Patil, Clayton K. Collings, Mia Madel Alfajaro, Yu Liang, Wesley L. Cai, Madison S. Strine, Renata B. Filler, Peter C. DeWeirdt, Ruth E. Hanna et al. · 2023 · Nature Genetics
48. Corona virus versus existence of human on the earth: A computational and biophysical approach
    Zainy Zehra, Manav Luthra, Sobia Manaal Siddiqui, Anas Shamsi, Naseem Akhtar Gaur, Asimul Islam · 2020 · International Journal of Biological Macromolecules
49. Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics
    Vijay Kumar · 2020 · International Immunopharmacology
50. How SARS-CoV-2 (COVID-19) spreads within infected hosts — what we know so far
    Sumana Sanyal · 2020 · Emerging Topics in Life Sciences
51. Screening of potent neutralizing antibodies against SARS-CoV-2 using convalescent patients-derived phage-display libraries
    Yongbing Pan, Jianhui Du, Jia Liu, Hai Wu, Fang Gui, Nan Zhang, Xiaojie Deng, Gang Song, Yufeng Li, Jia Lu et al. · 2021 · Cell Discovery
52. Keep out! SARS-CoV-2 entry inhibitors: their role and utility as COVID-19 therapeutics
    Lennox Chitsike, Penelope J. Duerksen-Hughes · 2021 · Virology Journal
53. Generation of a Sleeping Beauty Transposon-Based Cellular System for Rapid and Sensitive Screening for Compounds and Cellular Factors Limiting SARS-CoV-2 Replication
    Marek Widera, Alexander Wilhelm, Tuna Toptan, Johanna M. Raffel, Eric Kowarz, Fabian Roesmann, Finn Grözinger, Anna Lena Siemund, Vanessa Luciano, Marius Külp et al. · 2021 · Frontiers in Microbiology
54. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein
    Hongyue Li, Yuhang Zhang, Dong Li, Yong‐Qiang Deng, Hongde Xu, Chaoyue Zhao, Jiandong Liu, Dan Wen, Jianguo Zhao, Yongchun Li et al. · 2021 · Signal Transduction and Targeted Therapy
55. Molecular Virology of SARS-CoV-2 and Related Coronaviruses
    Yu-An Kung, Kuo-Ming Lee, Huan-Jung Chiang, Sheng‐Yu Huang, Chung-Jung Wu, Shin‐Ru Shih · 2022 · Microbiology and Molecular Biology Reviews
56. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
    Lucia Lisi, Pedro Miguel Lacal, Maria Luisa Barbaccia, Grazia Graziani · 2020 · Biochemical Pharmacology
57. The receptor binding domain of SARS-CoV-2 spike protein is the result of an ancestral recombination between the bat-CoV RaTG13 and the pangolin-CoV MP789
    Alejandro Flores-Alanis, Luisa Sandner-Miranda, Gabriela Delgado, Alejandro Cravioto, Rosario Morales-Espinosa · 2020 · BMC Research Notes
58. Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection
    Marco Infante, Camillo Ricordi, Rodolfo Alejandro, Massimiliano Caprio, Andrea Fabbri · 2020 · Expert Review of Anti-infective Therapy
59. Drugs against SARS‐CoV ‐2: What do we know about their mode of action?
    Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean‐Claude Guillemot, Bruno Coutard, Étienne Decroly · 2020 · Reviews in Medical Virology
60. SARS-CoV-2 Treatment Approaches: Numerous Options, No Certainty for a Versatile Virus
    Simona Alexandra Iacob, Diana Gabriela Iacob · 2020 · Frontiers in Pharmacology
61. D614G Substitution of SARS-CoV-2 Spike Protein Increases Syncytium Formation and Virus Titer via Enhanced Furin-Mediated Spike Cleavage
    Ya Wen Cheng, Tai‐Ling Chao, Chiao‐Ling Li, Sheng-Han Wang, Han‐Chieh Kao, Ya‐Min Tsai, Hurng‐Yi Wang, Chi-Ling Hsieh, You-Yu Lin, Pei‐Jer Chen et al. · 2021 · mBio
62. Natural and Recombinant SARS-CoV-2 Isolates Rapidly Evolve In Vitro to Higher Infectivity through More Efficient Binding to Heparan Sulfate and Reduced S1/S2 Cleavage
    Nikita Shiliaev, Tetyana Lukash, Oksana Palchevska, David K. Crossman, Todd Jason Green, Michael R. Crowley, Elena I. Frolova, Ilya V. Frolov · 2021 · Journal of Virology
63. Cell-Cell Fusion Mediated by Viruses and HERV-Derived Fusogens in Cancer Initiation and Progression
    Thomas Dittmar, Julian Weiler, Tianjiao Luo, Ralf Hass · 2021 · Cancers
64. Significant role of host sialylated glycans in the infection and spread of severe acute respiratory syndrome coronavirus 2
    Wakana Saso, Masako Yamasaki, Shin‐ichi Nakakita, Shuetsu Fukushi, Kana Tsuchimoto, Noriyuki Watanabe, Nongluk Sriwilaijaroen, Osamu Kanie, Masamichi Muramatsu, Yoshimasa Takahashi et al. · 2022 · PLoS Pathogens
65. Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
    Michael S. Piepenbrink, Jun‐Gyu Park, Ashlesha A. Deshpande, Andreas Loos, Chengjin Ye, Madhubanti Basu, Sanghita Sarkar, Ahmed Magdy Khalil, David Chauvin, Jennifer C. Woo et al. · 2022 · PLoS Pathogens
66. Membrane attachment and fusion of HIV-1, influenza A, and SARS-CoV-2: resolving the mechanisms with biophysical methods
    Geetanjali Negi, Anurag Sharma, Manorama Dey, Garvita Dhanawat, Nagma Parveen · 2022 · Biophysical Reviews
67. Trypsin enhances SARS-CoV-2 infection by facilitating viral entry
    Yeeun Kim, Guehwan Jang, Duri Lee, Nara Kim, Jeong Won Seon, Young-Hoan Kim, Changhee Lee · 2022 · Archives of Virology
68. How could we forget immunometabolism in SARS-CoV2 infection or COVID-19?
    Vijay Kumar · 2020 · International Reviews of Immunology
69. Pathogenesis, Symptomatology, and Transmission of SARS-CoV-2 through Analysis of Viral Genomics and Structure
    Halie M. Rando, Adam L. MacLean, Alexandra J. Lee, Ronan Lordan, Sandipan Ray, Vikas Bansal, Ashwin N. Skelly, Elizabeth Sell, John J. Dziak, Lamonica Shinholster et al. · 2021 · mSystems
70. Spike protein of SARS‐CoV‐2 activates macrophages and contributes to induction of acute lung inflammation in male mice
    Xiaoling Cao, Yan Tian, Vi Nguyen, Yuping Zhang, Chao Gao, Rong L. Yin, Wayne E. Carver, Daping Fan, Helmut Albrecht, Taixing Cui et al. · 2021 · The FASEB Journal
71. Nanomedicine: A Diagnostic and Therapeutic Approach to COVID-19
    Arjun Sharma, Konstantinos Kontodimas, Markus Bosmann · 2021 · Frontiers in Medicine
72. Pannexin-1 channel opening is critical for COVID-19 pathogenesis
    Ross H. Luu, Silvana Valdebenito, Eliana Scemes, Antonio Cibelli, David Conover Spray, Maximiliano Rovegno, Juan Enrique Tichauer, Andréa Cottignies-Calamarte, Arielle R. Rosenberg, Calude Capron et al. · 2021 · iScience
73. SARS-CoV-2 Infects Human ACE2-Negative Endothelial Cells through an αvβ3 Integrin-Mediated Endocytosis Even in the Presence of Vaccine-Elicited Neutralizing Antibodies
    Antonella Bugatti, Federica Filippini, Marta Bardelli, Alberto Zani, Paola Chiodelli, Serena Messali, Arnaldo Caruso, Francesca Caccuri · 2022 · Viruses
74. Omicron subvariant BA.5 efficiently infects lung cells
    Markus Hoffmann, Lok-Yin Roy Wong, Prerna Arora, Lu Zhang, Cheila Rocha, Abby E. Odle, Inga Nehlmeier, Amy Madeleine Kempf, Anja M. Richter, Nico Joël Halwe et al. · 2023 · Nature Communications
75. Host heparan sulfate promotes ACE2 super-cluster assembly and enhances SARS-CoV-2-associated syncytium formation
    Qi Zhang, Weichun Tang, Eduardo Stancanelli, Eunkyung Jung, Zulfeqhar Ali Syed, Vijayakanth Pagadala, Layla F. Saidi, Catherine Z. Chen, Peng Gao, Miao Xu et al. · 2023 · Nature Communications
76. Host Genetic Variants Potentially Associated With SARS-CoV-2: A Multi-Population Analysis
    Maria K. Smatti, Yasser A. Al-Sarraj, Omar Albagha, Hadi Mohamad Yassine · 2020 · Frontiers in Genetics
77. Generation of Chicken IgY against SARS‐COV‐2 Spike Protein and Epitope Mapping
    Yan Lü, Yajun Wang, Zhen Zhang, Jingliang Huang, Yao Meicun, Guobin Huang, Yuanyuan Ge, Peichun Zhang, Huaxin Huang, Yong Wang et al. · 2020 · Journal of Immunology Research
78. SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
    Gisela Canedo-Marroquín, Farides Saavedra, Catalina A. Andrade, Roslye V. Berríos-Rojas, Linmar Rodríguez‐Guilarte, María Cecilia Opazo, Claudia A. Riedel, Alexis M. Kalergis · 2020 · Frontiers in Immunology
79. Inclusion of cGAMP within virus-like particle vaccines enhances their immunogenicity
    Lise Chauveau, Anne Bridgeman, Tiong Kit Tan, Ryan D. D. Beveridge, Joe N. Frost, Pramila Rijal, Isabela Pedroza‐Pacheco, Thomas Partridge, Javier Gilbert‐Jaramillo, Michael L. Knight et al. · 2021 · EMBO Reports
80. A new possible route of airborne transmission caused by the use of a physical partition
    Jinjun Ye, Zhengtao Ai, Chen Zhang · 2021 · Journal of Building Engineering
81. Advanced Materials for SARS‐CoV‐2 Vaccines
    Moustafa T. Mabrouk, Wei‐Chiao Huang, Luis Martínez‐Sobrido, Jonathan F. Lovell · 2021 · Advanced Materials
82. The potential role of COVID-19 in the induction of DNA damage
    Pablo Pánico, Patricia Ostrosky‐Wegman, Ana María Salazar · 2022 · Mutation Research/Reviews in Mutation Research
83. Aprotinin treatment against SARS‐CoV‐2: A randomized phase III study to evaluate the safety and efficacy of a pan‐protease inhibitor for moderate COVID‐19
    F. Redondo Calvo, J. Padín, JR. Muñoz-Rodriguez, L. Serrano-Oviedo, P. López-Juárez, M. Porras-Leal, FJ González-Gasca, M. R. Martínez, R. P. Serrano, A. Cadena et al. · 2022 · European Journal of Clinical Investigation
84. Exosome-Mediated mRNA Delivery For SARS-CoV-2 Vaccination
    Shang Jui Tsai, Chenxu Guo, Alanna Sedgwick, Saravana kumar Kanagavelu, Justin B. Nice, Sanjana Shetty, Connie Landaverde, Nadia A. Atai, Stephen J. Gould · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
85. Should we discount the laboratory origin of COVID-19?
    Rossana Segreto, Yuri Deigin, Kevin McCairn, Alejandro Sousa, Dan Sirotkin, Karl M. Sirotkin, Jonathan J. Couey, Adrian Jones, Daoyu Zhang · 2021 · Environmental Chemistry Letters
86. Different Neutralization Sensitivity of SARS-CoV-2 Cell-to-Cell and Cell-Free Modes of Infection to Convalescent Sera
    Kruglova, Natalia, Siniavin, Andrei, Gushchin, Vladimir, Mazurov, Dmitriy · 2021 · Viruses
87. Propagation of SARS-CoV-2 in Calu-3 Cells to Eliminate Mutations in the Furin Cleavage Site of Spike
    John James Baczenas, Hanné Andersen, Sujatha Rashid, David A. Yarmosh, Nikhita P. Puthuveetil, Michael L. Parker, Rebecca Bradford, Clint Florence, Kimberly J. Stemple, Mark G. Lewis et al. · 2021 · Viruses
88. Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
    Alessandra Aiello, Saeid Najafi Fard, Delia Goletti · 2023 · Frontiers in Immunology
89. A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells
    Simon G. P. Funnell, Babak Afrough, John James Baczenas, Neil J. Berry, Kevin R. Bewley, Rebecca Bradford, Clint Florence, Yann Le Duff, Mark G. Lewis, Ryan V. Moriarty et al. · 2021 · npj Vaccines
90. SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1
    John Lokman Law, Michael R Logan, Michael Joyce, Abdolamir Landi, Darren J. Hockman, Kevin Crawford, Janelle Johnson, Gerald LaChance, Holly A. Saffran, Justin A. Shields et al. · 2021 · Vaccine
91. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein
    Shijian Zhang, Eden P. Go, Haitao Ding, Saumya Anang, John C. Kappes, Heather Desaire, Joseph Sodroski · 2021 · Journal of Virology
92. The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour
    A. Sofia F. Oliveira, Deborah K. Shoemark, Amaurys Ávila Ibarra, Andrew D. Davidson, Imre Berger, Christiane Schaffitzel, Adrian John Mulholland · 2021 · Computational and Structural Biotechnology Journal
93. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
    Timothy J.C. Tan, Zongjun Mou, Ruipeng Lei, Wenhao O. Ouyang, Meng Yuan, Ge Song, Raiees Andrabi, Ian A. Wilson, Collin Kieffer, Xinghong Dai et al. · 2023 · Nature Communications
94. Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release
    Hazel Stewart, Roberta Palmulli, Kristoffer H. Johansen, Naomi N. McGovern, Ola M. Shehata, George Carnell, Hannah K. Jackson, Jin S. Lee, Jonathan C. Brown, Thomas Burgoyne et al. · 2023 · EMBO Reports
95. Emergence and Evolution of a Prevalent New SARS-CoV-2 Variant in the United States
    Adrian A. Pater, Michael S. Bosmeny, Christopher L. Barkau, Katy N. Ovington, Ramadevi Chilamkurthy, Mansi Parasrampuria, Seth B. Eddington, Abadat O. Yinusa, Adam A. White, Paige E. Metz et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
96. Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking
    Chih-Feng Tien, Wan-Ting Tsai, Chun-Hwa Chen, Hui-Ju Chou, Mingzi M. Zhang, Jhe-Jhih Lin, En-Ju Lin, Shih-Syong Dai, Yueh‐Hsin Ping, Chia-Yi Yu et al. · 2022 · iScience
97. Glycosylation in SARS-CoV-2 variants: A path to infection and recovery
    Arya Aloor, Rajaguru Aradhya, Parvathy Venugopal, Bipin Gopalakrishnan Nair, Renuka Suravajhala · 2022 · Biochemical Pharmacology
98. ACE2 from Pipistrellus abramus bats is a receptor for HKU5 coronaviruses
    Nicholas Catanzaro, Ziyan Wu, Chengcheng Fan, Victoria A. Jefferson, Anfal Abdelgadir, Alexandra Schäfer, Boyd L. Yount, Pamela J. Björkman, Ralph Steven Baric, Michael C. Letko · 2025 · Nature Communications
99. Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein
    Thomas Lemmin, David Kalbermatter, Daniel Harder, Philippe Plattet, Dimitrios Fotiadis · 2020 · Journal of Structural Biology X
100. Susceptibility to SARS-CoV-2 of Cell Lines and Substrates Commonly Used to Diagnose and Isolate Influenza and Other Viruses
     Li Wang, Xiaoyu Fan, Gaston Bonenfant, Dan Cui, Jaber Hossain, Nannan Jiang, Gloria P. Larson, Michael Currier, Jimma Liddell, Malania M. Wilson et al. · 2021 · Emerging infectious diseases